Cardiome Pharma (CRME) Tops Q3 EPS by 1c

Cardiome Pharma (NASDAQ: CRME) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $5.68 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c